Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.63 |
| ▸ | TK2 | O00142 | 2/20 | 0.58 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.54 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.54 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.54 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.54 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.47 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HBB | P68871 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TYMP | P19971 | 1/20 | 0.45 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Netivudine SCHEMBL913358 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL18052692 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL112727 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL112726 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL9538356 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL1585773 | 1.00 | PYGM (0.63) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL462884 | 0.97 | PYGM (0.60) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Netivudine SCHEMBL22028728 | 0.92 | P2RY6 (0.57) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL21276349 | 0.91 | PYGM (0.51) | PYGMTK2DNPH1P2RY2TSHR | |
| SCHEMBL1060638 | 0.90 | PYGM (0.51) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334300-B2 | Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates | MBC PHARMA, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| EP-1499627-A2 | NUCLEASE RESISTANT CHIMERIC OLIGONUCLEOTIDES | ISIS Pharmaceuticals, Inc. (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20030175906-A1 | Nuclease resistant chimeric oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20030158403-A1 | Nuclease resistant chimeric oligonucleotides | ISIS PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | disclosed |
| WO-2003004602-A2 | NUCLEASE RESISTANT CHIMERIC OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158403-A1 | Nuclease resistant chimeric oligonucleotides | RNASE1, DIS3, DCLRE1B | PYGM 1221/4885TK2 555/4885SLC28A1 985/4885 |
| US-20030175906-A1 | Nuclease resistant chimeric oligonucleotides | DIS3, RNASE1, DCLRE1B | PYGM 1200/4885TK2 504/4885SLC28A1 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.